Zobrazeno 1 - 10
of 19
pro vyhledávání: '"ÖZGECAN DÜLGAR"'
Autor:
Wei Wang, Andrew Haydon, Rebecca Johnson, Elisabeth Livingstone, Zeynep Eroglu, Grant A McArthur, Douglas B Johnson, Prachi Bhave, Georgina Long, Adnan Khattak, Matteo S Carlino, Johanna Mangana, Katharina Kahler, Angela Hong, Serigne N Lo, Hui-Ling Yeoh, Alexander Maxwell Menzies, Ozgecan Dulgar, Georg C Lodde, Axel Hausschild
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background In patients with stage III melanoma, despite surgical resection and adjuvant systemic therapy, locoregional recurrences still occur. The randomized, phase III Trans-Tasman Radiation Oncology Group (TROG) 02.01 trial demonstrated that adjuv
Externí odkaz:
https://doaj.org/article/35448e0e51c54b988eb95ba45ce8d0d2
Publikováno v:
European Journal of Breast Health, Vol 16, Iss 4, Pp 276-281 (2020)
Objective:Triple-negative-breast-cancer (TNBC) is a very heterogenous disease some of which are very aggressive and have poor prognosis. No targeted therapy is available. Immune response and tumor-infiltrating lymphocytes (TIL) can be related to long
Externí odkaz:
https://doaj.org/article/7804ae5a81cf4f3e9cc97010c30584b1
Autor:
Özgecan Dülgar, Başak Bala Öven, Muhammed Mustafa Atcı, Rukiye Arıkan, Seval Ay, Murat Ayhan, Oğuzhan Selvi, Deniz Tataroglu Ozyukseler, Ertuğrul Bayram, Erkan Özcan, Ayşe İrem Yasin, Mahmut Gümüş
Publikováno v:
Expert Review of Anticancer Therapy. 22:773-780
Background Triple-negative-breast-cancer (TNBC) has a poor prognosis if pathologic complete response (pCR) cannot be achieved following neoadjuvant chemotherapy (NAC). The group of patients that benefit most from adjuvant capecitabine remains unclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0571c521d2d9822c93b445b5fe9351bd
https://doi.org/10.1080/14737140.2022.2076670
https://doi.org/10.1080/14737140.2022.2076670
Autor:
Tuğba Başoğlu, Abdullah Sakin, Cihan Erol, Ercan Özden, Devrim Çabuk, Ebru Çılbır, Deniz Tataroğlu Özyükseler, Murat Ayhan, Mehmet Ali Şendur, Mutlu Dogan, Berna Öksüzoğlu, Melek Karakurt Eryılmaz, Özlem Er, Elif Şenocak Taşçı, Neslihan Özyurt, Özgecan Dülgar, Miraç Özen, İlhan Hacıbekiroğlu, İrem Öner, Esma Türkmen Bekmez, Hasan Çağrı Yıldırım, Şuayib Yalçın, Semra Paydaş, Emre Yekedüz, Asude Aksoy, Melike Özçelik, Abdilkerim Oyman, Elvina Almuradova, Bülent Karabulut, Nazan Demir, Murat Dinçer, Nuriye Özdemir, Dilek Erdem, Naziye Ak, Ali İnal, Derya Kıvrak Salim, Gülhan İpek Deniz, Teoman Şakalar, Ahmet Gülmez, Turgut Kaçan, Özlem Özdemir, Özkan Alan, Çağlar Ünal, Yusuf Karakaş, Serdar Turhal, Perran Fulden Yumuk
Publikováno v:
Journal of Chemotherapy. 35:142-149
Neoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare the efficacy and toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1c2284ea2d913751fc2b471ed5ebfcc
https://doi.org/10.1080/1120009x.2022.2073159
https://doi.org/10.1080/1120009x.2022.2073159
Autor:
Seval Ay, Muhammed Mustafa Atcı, Rukiye Arıkan, Özgecan Dülgar, Deniz Tataroğlu Özyükseler, Nail Paksoy, İzzet Doğan, Buğra Öztosun, Didem Taştekin, Başak Bala Öven, Mahmut Gümüş
Publikováno v:
Journal of Chemotherapy. 34:465-471
Pancreas cancer (PCa) is one of the mortal cancer types with ranking as fourth leading cancer death in both sexes together. FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GNP) are approved as first-line metastatic treatment in PCa. The aim of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f24abf478c56e94abd1b17617a1826
https://doi.org/10.1080/1120009x.2022.2026125
https://doi.org/10.1080/1120009x.2022.2026125
Publikováno v:
Journal of Oncological Sciences. 8:113-118
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ca9d352235b1f7be1def064803dffd7
https://doi.org/10.37047/jos.2022-91240
https://doi.org/10.37047/jos.2022-91240
Initial albumin-bilirubin grade as a prognostic indicator of pancreatic cancer with liver metastasis
Autor:
Seval AY, Muhammed Mustafa ATCI, Rukiye ARIKAN, Özgecan DÜLGAR, Deniz TATAROĞLU ÖZYÜKSELER, Mahmut GÜMÜŞ
Objective: Pancreatic cancer (PCa) is the fourth leading cause of cancer-related deaths. Thus, there is a need for prognostic in-dicators that can aid in disease classification and subsequent selection of appropriate treatment options. Albumin-biliru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52b027ba53287f95f3a5fb16ece9d012
https://hdl.handle.net/11424/289005
https://hdl.handle.net/11424/289005
Publikováno v:
Anadolu Kliniği Tıp Bilimleri Dergisi.
Amaç: Obezite, meme kanseri gelişiminde etkili olabilen değiştirilebilir bir risk faktörüdür. Bozulmuş açlık glikozu ise metabolik sendromun bir bileşenidir ve diyabet gelişimi için önemli bir risk faktörüdür. Metabolik sendromun bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::daa7e4eeb3773b71cacf81872daecbe1
https://doi.org/10.21673/anadoluklin.1135546
https://doi.org/10.21673/anadoluklin.1135546
Publikováno v:
Turkish Journal of Clinics and Laboratory.
Aim: Endometrial carcinoma (EC) is the most common female reproductive system cancer in Europe and fifth leading reason of death in female cancer in worldwide. Hormone receptors are the main modulator of endometrium functions. Aim of present study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c48cbad4a3e6bd3b8d65f4a80c0d1319
https://doi.org/10.18663/tjcl.1143872
https://doi.org/10.18663/tjcl.1143872
Autor:
Özgecan Dülgar, Mustafa Basak, Deniz Tataroğlu Özyükseler, Mahmut Emre Yıldırım, Seval Ay, Mahmut Gumus
Publikováno v:
Journal of the College of Physicians and Surgeons Pakistan. 31:651-656
OBJECTIVE To determine the relevance between the cut-off level of cancer antigen 125 (CA 125) level and long-term prognosis in high-grade serous ovarian cancer (HGSCs). STUDY DESIGN Observational study. PLACE AND DURATION OF STUDY Departments of Onco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a341706cf8267db4c70113e585ee7d2a
https://doi.org/10.29271/jcpsp.2021.06.651
https://doi.org/10.29271/jcpsp.2021.06.651